Comparative Pharmacology
Head-to-head clinical analysis: NALLPEN IN PLASTIC CONTAINER versus PENICILLIN G POTASSIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALLPEN IN PLASTIC CONTAINER versus PENICILLIN G POTASSIUM.
NALLPEN IN PLASTIC CONTAINER vs PENICILLIN G POTASSIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nallpen is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically active against beta-lactamase-producing Staphylococcus aureus.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
Nafcillin 1-2 g IV every 4 hours for moderate to severe infections; for MSSA bacteremia or endocarditis, 2 g IV every 4 hours.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
None Documented
None Documented
0.9-1.2 hours; prolonged in renal impairment (up to 7-10 hours in anuria); requires dose adjustment for CrCl <30 mL/min
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
Primarily renal (60-80% unchanged drug via glomerular filtration and tubular secretion); biliary/fecal: minor (<5%)
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic